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RADIATION ONCOLOGY PHYSICS

Evaluation of plan quality and treatment efﬁciency for
single‐isocenter/two‐lesion lung stereotactic body
radiation therapy
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Author to whom correspondence should be
addressed. Damodar Pokhrel
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Telephone: (859) 323-7599;
Fax: (859) 257-4931

Abstract
Purpose/objectives: To evaluate the plan quality and treatment delivery efﬁciency
of single‐isocenter/two‐lesions volumetric modulated arc therapy (VMAT) lung
stereotactic body radiation therapy (SBRT).
Materials/methods: Eight consecutive patients with two peripherally located early
stage nonsmall‐cell‐lung cancer (NSCLC) lung lesions underwent single‐isocenter
highly conformal noncoplanar VMAT SBRT treatment in our institution. A single‐isocenter was placed between the two lesions. Doses were 54 or 50 Gy in 3 and 5
fractions respectively. Patients were treated every other day. Plans were calculated
in Eclipse with AcurosXB algorithm and normalized to at least 95% of the planning
target volume (PTV) receiving 100% of the prescribed dose. For comparison, two‐
isocenter plans (isocenter placed centrally in each target) were retrospectively created. Conformity indices (CIs), heterogeneity index (HI), gradient index (GI), gradient
distance (GD), and D2cm were calculated. The normal lung V5, V10, V20, mean lung
dose (MLD) and other organs at risk (OARs) doses were evaluated. Total number of
monitor units (MUs), beam‐on time, and patient‐speciﬁc quality assurance (QA)
results were recorded.
Results: The mean isocenter to tumor distance was 6.7 ± 2.3 cm. The mean combined PTV was 44.0 ± 23.4 cc. There was no clinically signiﬁcant difference in CI,
HI, GD, GI, D2cm, and V20 including most of the OARs between single‐isocenter
and two‐isocenter lung SBRT plans, evaluated per RTOG guidelines. However, for
single‐isocenter plans as the distance between the lesions increased, the V5, V10,
and MLD increased, marginally. The total number of MUs and beam‐on time was
reduced by a factor of 1.5 for a single‐isocenter plan compared to a two‐isocenter
plan. The single‐isocenter/two‐lesions VMAT lung SBRT QA plans demonstrated an
accurate dose delivery of 98.1 ± 3.2% for clinical gamma passing rate of 3%/3 mm.
Conclusion: The SBRT treatment of two peripherally located lung lesions with a
centrally placed single‐isocenter was dosimetrically equivalent to two‐isocenter
plans. Faster treatment delivery for single‐isocenter treatment can improve patient

---------------------------------------------------------------------------------------------------------------------------------------------------------------------This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2018 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Medicine.
118

|

wileyonlinelibrary.com/journal/jacmp

J Appl Clin Med Phys 2019; 20:1:118–127

SANFORD

|

ET AL.

119

compliance and reduce the amount of intrafraction motion errors for well‐suited
patients.
PACS

87.55.k
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1 | INTRODUCTION

With the recent technological advances, VMAT may provide
highly conformal radiation dose delivery with faster delivery

For medically inoperable stage I/II nonsmall‐cell lung cancer (NSCLC)

times.17–20 The VMAT lung SBRT simultaneously optimizes gantry

patients, several Phase I/II trials have shown that the use of stereo-

speed, multileaf collimator (MLC) position and high dose‐rate (FFF,

tactic body radiation therapy (SBRT) treatment for solitary lung

ﬂattening ﬁlter free mode) to provide highly conformal dose distribu-

lesions representing the primary tumor mass is safe, effective, and

tions to the planning target volume (PTV) while minimizing dose to

has a high cure rate comparable to surgery.1–7 In these studies, med-

adjacent OARs. Reducing treatment time would improve patient

ically inoperable patients with early‐stage NSCLC who underwent

compliance which helps reduce error due to motion, and promote

SBRT had 3‐yr primary tumor local control rates of up to 98% and a

more efﬁcient clinic ﬂow. For multiple brain metastases, recent stud-

low risk of treatment‐related toxicity.

ies have shown that single‐isocenter VMAT can provide highly con-

In the setting of either multiple primary lung cancers or limited

formal radiosurgical dose distributions, excellent plan quality and

metastatic lesions to the lungs (oligometastastic), SBRT presents a rel-

safe and faster treatment delivery compared to conventional multi‐

atively new treatment opportunity. Optimal treatment planning must

isocenter technique.21–23 However, there is little literature in the

consider microscopic disease extension around the visible mass and

medical physics community on the treatment of multiple lung lesions

allow for tumor movement, primarily due to respiration. Multiple

using single‐isocenter VMAT‐SBRT technique.

metachronous or synchronous lung cancers are relatively common and

A few studies have examined the use of single‐isocenter SBRT for

have been managed by SBRT.8 Based on Phase I/II trials of SBRT in

multiple lung lesions. A study by Trager et al.24 discusses the use of a

the management of oligometastastic lung lesions, for patients with

technique that utilizes a single‐isocenter with distinct optimizations

one to three tumors, up to ﬁve tumors (with curative intent) and more

for extracranial radiosurgery. Gulam et al.25 examined six patients and

than ﬁve tumors with palliative treatment have been reported.

found that the criteria set forth by Radiation Therapy Oncology Group

9,10

Rusthoven and colleagues treated 38 patients, 63 total tumors, with

(RTOG) study 0915 protocol was met with regard to CI, but not some

lung SBRT of total dose of 48–60 Gy in 3 fractions. Actuarial local con-

other critical dosimetric parameters. A retrospective study in total ele-

trol rates at 1‐ and 2‐yr after SBRT was 100% and 96% respectively.10

ven patients by Quan et al.26 showed no difference in multiple dosi-

SBRT to multiple lung lesions presents with technical challenges

metric parameters between single‐isocenter VMAT plans (four single‐

and can be treated either sequentially with separate treatment plans

isocenter VMAT plans were compared) and multi‐isocenter intensity‐

or synchronously to all lesions. However, the location and geometry of

modulated SBRT to the lung. Still, the ability of a single‐isocenter

synchronous plans can be challenging since minor inaccuracies of

treatment to two or more lung lesions to deliver curative treatment

patient setup can result in geometric misses. Attention must be paid to

plans in adherence with RTOG 0915 dosimetric compliance criteria

overlapping doses to organs at risk (OARs) and respiratory control is

has not been fully explored. In this report we present our recently

critical since different parts of the lung can move independently.

adopted treatment method utilizing single‐isocenter VMAT plan for

Sequential treatment plans for each individual tumor, using a multi‐iso-

SBRT of two lung lesions evaluated per RTOG 0915. For complete-

centric technique requires relatively longer planning and treatment

ness, the original single‐isocenter lung SBRT plans and retrospectively

delivery time. Safe and effective delivery of SBRT of lung requires pre-

generated conventional two‐isocenter lung SBRT plans were com-

cise, highly conformal treatment planning and delivery techniques.11–13

pared via their protocol compliance, plan quality, dose to critical struc-

In the past decades, treatment techniques for lung SBRT included Lin-

tures, treatment delivery efﬁciency, and accuracy.

ear accelerator‐based 3D‐conformal radiation therapy, intensity modulated radiation therapy (IMRT), volumetric modulated arc therapy
(VMAT) (RapidArc,Varian Inc., Palo Alto, CA, USA), CyberKnife, and
helical Tomotherapy (Accuray Inc., Sunnyvale, CA, USA). However, as
the complexity of the technology has evolved, treatment has required

2 | MATERIALS AND METHODS
2.A | Patient setup and target delineation

very high total monitor units (MU) and relatively long treatment times

A total of eight sequential patients were included in this retrospec-

to deliver a highly conformal plan and spare OARs.14–16

tive study, all of whom had two peripherally located Stage I NSCLC
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lesions. The patients were immobilized using Body Pro‐Lok™ platform

dose calculation grid‐size. Dose to medium reporting mode was

(CIVCO system, Orange City, IA) in the supine position with their

selected. All clinical plans were inversely optimized using variation

arms above their head with abdominal compression, potentially

of gantry rotation speed, dose rate and MLC positions. The gener-

reducing diaphragmatic motion to less than or equal to 1.0 cm. Con-

alized normal tissue objective (NTO) parameters were used to con-

ventional 3D CT scans and respiration‐correlated 4D CT scans were

trol the gradients for single‐isocenter clinical plan. As recommended

acquired on a GE Lightspeed 16 slice CT scanner (General Electric

by Varian, in our department, we used the following NTO parame-

Medical Systems, Waukesha, WI) with 512 × 512 pixels at 2.5 mm

ters for lung SBRT plans: NTO with high priority of 150 with dis-

slice thickness in the axial cine mode. Varian's Real Time Position

tance to target border of 0.1 cm. Start dose of 100.0% and end

Management Respiratory Gating System (version 1.7) was used for

dose of 40% was used with a fall‐off factor of 0.5/mm. Moreover,

collection of 4D CT data. All 10 phases of 4D CT slices and respira-

the ring structures of 5, 10, and 20 annulus from each lesion with

tory motion signal were transferred to an Advantage 4D Worksta-

5 mm gaps were generated to enforce the high dose regions (typi-

tion (General Electric Medical Systems, San Francisco, CA), where

cally enforcing maximum 120% hotspot inside each ITV) and mini-

the maximum intensity projection (MIP) images were generated after

mize the intermediate dose spillage. All the planning objectives

a phase binning of the 4D CT images. In addition to the MIP images,

were per RTOG 0915 guidelines. The patients were treated every

the motion of both tumors was evaluated by an experienced physi-

other day per lung SBRT protocol.

cist to afﬁrm synchronous tumor motion that was less than 1 cm.
The regular 3D CT scan and the MIP images were imported into the
Eclipse treatment planning system (TPS) (version 13.0, Varian Medi-

2.B.2 | Two‐isocenter VMAT plan

cal Systems, Palo Alto, CA) and coregistered for target contouring.

For comparison, the SBRT treatment plans for all patients were ret-

Gross tumor volumes (GTV) and internal tumor volumes (ITV) were

rospectively replanned with a conventional two‐isocenter approach.

delineated on the 3D CT images with references to the MIP images.

Individual isocenters were placed in the geometric center of each

Planning target volumes (PTV) were generated by adding non‐uni-

tumor. For each target, the plans were generated using 3–4 non-

form 5–10 mm margins to the ITV to accommodate the patient

coplanar partial arcs, similar to single‐isocenter plan. Collimator rota-

setup uncertainties based on tumor size, location and synchronous

tions and jaw tracking were applied. The plan for the ﬁrst tumor

tumor motion. The critical structures, such as bilateral lungs exclud-

(PTV1) was ﬁrst computed using same RTOG guidelines as described

ing the ITV (normal lung), spinal cord, ribs, heart, great vessels,

before. The plan for PTV1 was then used as the base‐plan for gener-

esophagus, and skin were delineated on the 3D CT images.

ating the plan for the second tumor (PTV2) in order to allow full
scatter contributions from both plans. All the planning objectives

2.B | Treatment planning

used were the same as the single‐isocenter plan including the NTO

2.B.1 | Clinical single‐isocenter VMAT Plan

parameters and ring structures. Dosimetric parameters for the target
coverage and the adjacent OARs, including normal lung, were evalu-

Highly conformal, clinically optimal VMAT treatment plans were

ated.

generated using 3–4 non‐coplanar partial arcs (5–10°, couch kicks
were used for arcs) for the Truebeam linear accelerator (Varian,
Palo Alto, CA) with millennium MLC and a 6 MV‐FFF (1400 MU/

2.C | Plan evaluation

min) beam. A single‐isocenter was placed approximately between

Each plan was evaluated for the target coverage and the dose to

the two lesions. As the isocenter location does not need to be

OARs. For example, using the percentage prescribed isodose volume

exactly in the middle of the lesions, an offset allowing for the gan-

and target size, the RTOG conformity index (CI) was calculated as

try to rotate in a partial arc can be made. For those arcs, collimator

follows:27

angles were chosen in such a way that the opening of the MLC
between tumors was minimized while the gantry rotates around

RTOG CI ¼

the patient. Additionally, jaw tracking was used to further minimize

Rx Isodose Volume
PTV volume

(1)

the out of ﬁeld leakage dose. The isocenter to tumors distance

Ideally, CI = 1.0, implying a perfectly conformal plan. The RTOG

was the maximum 3D‐linear distance from the single‐isocenter loca-

recommendation for the CI is <1.2 with 1.2–1.5 being acceptable

tion to the geometric center of the individual tumor/isocenter. This

with minor deviations. In addition, the Paddick conformation number

distance was calculated in the TPS using the x‐, y‐, and z‐ primary

(CN) was calculated by:28

coordinates of the tumor centers. This distance was estimated to
Paddick CN ¼

evaluate the normal lung doses as a function of isocenter distance
from the targets. A dose of 54 or 50 Gy in 3 and 5 fractions was

ðTVPIV Þ2
ðTV  PIVÞ

(2)

prescribed to the PTV D95%. All clinical treatment plans were cal-

where TVPIV is the target volume covered by the prescription iso-

culated using the Eclipse TPS with Acuros‐XB (version 13.6.0, Var-

dose volume, TV is the target volume and PIV is the prescription iso-

ian Medical Systems, Palo Alto, CA) algorithm on the 3D CT

dose volume. CN = 1.0 would be ideal. The heterogeneity index (HI)

images for heterogeneity corrections with a 2.0 × 2.0 × 2.0 mm3

was determined by:

SANFORD
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HI ¼

D10%
D95%

(3)

where D10% is the dose to the hottest 10% of the PTV and D95%

121

3 | RESULTS
3.A | Target coverage and normal lung dose

is the dose to the 95% of the PTV coverage. The intermediate dose
spillage was evaluated by using, gradient index (GI), D2cm and gradi-

All patients were treated with a single‐isocenter VMAT plan in our
clinic, which utilized 2–4 noncoplanar partial arcs. The prescription

ent distance (GD). The GI was given by:

dose was 50–54 Gy in 3–5 fractions for at least 95% of the PTV
R50%
GI ¼
R100%

(4)

receiving 100% of the prescribed dose. The single‐isocenter to
tumors distance was calculated in the TPS using the x‐, y‐, and z‐ pri-

where R50% is the ratio of 50% prescription isodose volume to the

mary coordinates of the tumor centers, as described above. The

PTV and R100% is the ratio of 100% prescription isodose volume to

isocenter to tumor distance was approximately 3.7 to 9.6 cm (mean,

the PTV. Per RTOG, depending on the target size, a GI of 3.0–6.0 is

6.7 ± 2.3 cm). The mean combined PTV was 44.0 ± 23.4 cc (range,

desirable. Similarly, D2cm is the maximum dose, in percent of dose

20.5–91.8 cc). The DVHs for both single‐isocenter and two‐isocenter

prescribed, at 2 cm from the PTV in any direction; and the GD, is

treatment plans are shown in Fig. 1 for patient #8. In this case, both

the average distance from 100% prescription dose to 50% of the

planning approaches produced dosimetrically equivalent plans. How-

prescription dose. Although, RTOG only recommended normal lung,

ever, the treatment delivery time for the single‐isocenter technique

V20 < 10% (10–15% was acceptable with minor deviations), we

is reduced by a factor of 1.5. That was just a reported treatment

have evaluated V5, V10, and mean lung dose (MLD) for normal lung

delivery time, the actual patient setup and veriﬁcation for the second

for all plans.

isocenter with two‐isocenter plan would take extra‐time, prolonging
the treatment delivery.
Figure 2 displays a sagittal view of both single‐isocenter and

2.D | Dose to other OARs
In addition to the lung dose, all the clinical single‐isocenter plans
were evaluated for dose to spinal cord, heart, esophagus, trachea, ribs, and skin per RTOG guidelines. The dose volume histogram parameters were compared between the single‐isocenter
and the two‐isocenter plans. The mean and standard deviation
values for each of the dose metrics were compared using paired
t tests for single‐isocenter vs two‐isocenter computed dosimetric
parameters for the OARs dose tolerances using an upper bound

two‐isocenter treatment plans for the same patient (#8). In this case,
the normal lung V5 and V10 were similar; V20 was slightly higher
with single‐isocenter plan compared to two‐isocenter plan. However,
both plans met the RTOG compliance criteria for the target coverage
(see Table 1), normal lung and the other OARs dose tolerances.
Detail of the plan comparison for target coverage including
tumor location and the tumors distance from the isocenter are
shown in Table 1.
All lung SBRT plans were acceptable per RTOG guidelines for

of P < 0.05.

the high (CI, HI) and intermediate dose spillage (GI and D2cm). In

2.E | Delivery efﬁciency and accuracy

HI, GD, GI, and D2cm between single‐isocenter and two‐isocenter

addition, similar results were shown for the Paddick CN between
the two plans. No clinically signiﬁcant difference was observed in CI,
lung SBRT plans evaluated per RTOG guidelines by the treating

The dose delivery efﬁciency of each lung SBRT plan was evaluated

physician. However, the GD values were slightly higher with single‐

based on total number of MU and actual beam‐on time. For the

isocenter plan of about 3–5 mm, especially for the larger tumor dis-

single‐isocenter plan, actual beam on time was recorded at the treat-

tance from the isocenter compared to two‐isocenter plan. Clinical

ment machine while delivering the VMAT‐SBRT QA plan. Delivery

signiﬁcance of higher GD values, compared to relatively faster deliv-

accuracy of the VMAT‐SBRT QA plan was evaluated by physically

ery of single‐isocenter plan, may need to be explored.

measuring the 2D dose distribution of each plan using an Octavius

The absolute differences between single‐isocenter and two‐iso-

phantom (PTW, Freiburg, Germany). All QA plans were delivered at

center plans for normal lung V20, V10, V5, and MLD were listed in

the machine the day before the patient's 1st treatment. The mea-

the Table 2. All patients had V20 < 10–15% for both treatment

sured cumulative 2D dose plan was compared with the computed

plans. A statistically insigniﬁcant difference (P = 0.09) was found for

dose distributions calculated on the Octavius QA phantom plan by

the normal lung V20 between two plans. However, V10, V5, and

the TPS. Upon completion of delivered dose, data were analyzed

MLD increases slightly with single‐isocenter plan compared to two‐

with Octavius MEPHYSTO Navigator (VeriSoft Patient Plan Veriﬁca-

isocenter plan, giving statistically signiﬁcant differences (P = 0.03,

tion, Version 6.3, PTW) using the standard clinical gamma passing

0.01 and 0.03 respectively). Statistically signiﬁcant P‐values are high-

rate criteria of 3%/3 mm maximum dose difference and distance‐to‐

lighted in bold (see Table 2). Although, V10, V5, and MLD had

agreement (DTA) with 10% threshold as well as point dose. Since

shown statistically signiﬁcant differences, the absolute differences

the two‐isocenter plans were not used for patient treatment, no

were on the order of less than 0.8% for V20, 2.8% for V10 and

VMAT QA was done. The beam on time was estimated by using

6.5% for V5) and less than 60 cGy for MLD, on average, therefore,

dose rates of 1400 MU/min for these plans.

we do not expect the differences would be clinically signiﬁcant.
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F I G . 1 . This shows the dose volume histogram comparison for the target coverage (for both PTV1 and PTV2). The ITVs (red) and a few OAR
such as total normal lung (light blue), heart (dark blue), ribs (green), and spinal cord (orange) are shown for patient #8. Prescription dose was
54 Gy in three fractions. The square symbols representing the single‐isocenter plan, and the triangle symbols representing the two‐isocenter
plan. Both plans were normalized to at least 95% of PTV received 100% of the prescribed dose. In this case, the isocenter to tumors distance
was about 4 cm; the dosimetrically equivalent plans were generated using single‐isocenter technique, as demonstrated, with similar target
coverage and dose to the OARs.

F I G . 2 . This is a comparison of isodose distributions in sagittal view for the same patient #8 generated via single‐isocenter and two‐
isocenter plans. In the right panel a single‐isocenter location is shown by the intersection of the cross‐hair; in the left panel two‐isocenter plan
sum is shown for the both targets (PTV1 and PTV2). Target volumes contoured include both ITVs (red, innermost) followed by PTVs (orange
and green, outermost). Higher isodose lines, such as 54 Gy (100%), 51.3 Gy (95%), 48.6 Gy (90%), 43.2 Gy (80%), exhibit sharp dose fall off for
the both plans, including 27.0 Gy (50%) isodose line (blue). In both plans, the hotspot, 120% isodose line (thick‐orange) was shown in the
middle of the ITV. Other OARs such as ribs and lung contours are shown. Purple color rings were contoured to calculate D2cm (%) for each
target.

The ratios between single‐isocenter and two‐isocenter plans for

D0.35cc), heart (Dmax and D15cc), esophagus (Dmax and D5cc), trachea

the V20, V10, and V5 as a function of isocenter to tumors distance

(Dmax and D4cc), ribs (Dmax and D1cc), and skin (Dmax and D10cc) were

can be seen in Fig. 3. When the isocenter to tumor distance

evaluated per SBRT protocol guidelines.

increased, the low dose volume to the normal lung, such as V5 and

The average values of maximum doses to spinal cord, ribs, and

V10, was slightly increased. However, two of eight patients had

skin were similar (also see the average of the ratios in Table 3)

lower values of V20 with single‐isocenter plan.

between the two planning methods. Although, the average values
of the absolute dose differences and ratios for heart, esophagus

3.B | Dose to other OARs

and trachea were slightly higher with single‐isocenter plan, the
average absolute dose differences were up to 1–2 Gy. While eval-

A comparison of other OARs dosimetric parameters for single‐iso-

uating those plans per SBRT protocol's guidelines, those values

center and two‐isocenter plans for all eight lung SBRT patients is

met the protocol criteria, therefore, the differences were not

presented in Table 3. Critical organs such as spinal cord (Dmax, and

deemed

clinically

signiﬁcant.

Almost

all

P‐differences

were

SANFORD
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T A B L E 1 Comparison of plan evaluation parameters for single‐isocenter vs two‐isocenter treatment plans of all eight lung SBRT patients.
Lesion 1 (PTV1 plan) and Lesion 2 (PTV2 plan) and two‐isocenter (Two‐iso) plan sum.
Patient
no.
1

Plan type and
tumor location

Combined
PTV (cc)

HI

GI

0.75

1.16

6.6

47.9

0.90

Lesion 2, LLL

16.1

1.01

0.84

1.17

4.1

41.4

0.95

Two‐iso (plan sum)

21.1

1.05

0.81

1.18

4.8

47.6

0.97

1.05

0.79

1.16

5.0

56.5

1.20

Lesion 1, LUL

30.7

1.01

0.83

1.11

4.2

57.3

1.21

Lesion 2, RUL

43.6

0.99

0.84

1.22

3.6

55.2

1.18

Two‐iso (plan sum)

74.3

1.02

0.80

1.23

4.2

60.2

1.24

1.02

0.82

1.21

4.6

62.8

1.75

Lesion 1, LLL

16.2

1.05

0.76

1.17

4.8

50.8

1.05

Lesion 2, RUL

34.9

1.19

0.68

1.08

5.5

69.2

1.43

Two‐iso (plan sum)

51.1

1.26

0.70

1.26

5.4

76.3

1.49

1.29

0.67

1.39

6.4

80.5

1.78

Lesion 1, LLL

8.6

1.03

0.80

1.17

4.8

43.2

0.87

Lesion 2, RUL

26.6

1.01

0.84

1.20

4.1

51.8

1.11

Two‐iso (plan sum)

35.2

Single‐isocenter
5

1.22

4.9

55.9

1.21

1.18

5.5

53.6

1.45

80.9

0.99

0.83

1.15

3.3

56.1

1.34

10.9

1.02

0.72

1.21

5.0

48.7

0.97

Two‐iso (plan sum)

91.8

1.01

0.81

1.17

3.9

57.6

1.38

1.02

0.81

1.16

4.1

56.4

1.68

Lesion 1, Ant. LLL

19.6

1.04

0.77

1.16

4.3

49.3

1.02

Lesion 2, Post. LLL

7.7

1.20

0.63

1.20

6.7

44.8

1.00

Two‐iso (plan sum)

27.3

1.09

0.72

1.19

5.6

50.3

1.11

1.03

0.76

1.17

5.3

48.7

1.38

Lesion 1, RUL

13.6

1.04

0.67

1.10

5.3

48.0

1.04

Lesion 2, LUL

17.2

1.02

0.78

1.05

4.5

48.6

1.03

Two‐iso (plan sum)

30.8

1.05

0.62

1.11

5.6

51.4

1.09

1.04

0.70

1.16

5.2

48.6

1.43

13.5

0.99

0.83

1.19

4.3

46.5

0.94

Lesion 2, Ant. RUL

8.0

1.00

0.80

1.18

5.1

45.4

0.90

Two‐iso (plan sum)

21.5

Single‐isocenter
8

0.76
0.74

Lesion 2, RLL

Single‐isocenter
7

1.07
1.16

Lesion 1, LUL

Single‐isocenter
6

GD
(cm)

1.08

Single‐isocenter
4

D2cm
(%)

5.0

Single‐isocenter
3

Paddick
CN

Lesion 1, LUL

Single‐isocenter
2

RTOG
CI

Lesion 1, Post.
RUL

Single‐isocenter

1.04

0.81

1.19

4.8

47.0

1.13

1.03

0.81

1.19

5.1

48.9

1.23

Isocenter to
tumors distance
(cm)
5.2

9.5

9.6

4.6

8.4

4.8

4.9

3.7

T A B L E 2 Normal lung doses statistics between single‐isocenter and two‐isocenter plans for all eight lung SBRT patients. Data were presented
as mean ± standard deviation (range) and P‐values.
Plan type

V20 (%)

V10 (%)

V5 (%)

MLD (Gy)

Two‐isocenter

6.7 ± 2.7 (2.9 to 12.2)

18.2 ± 6.7 (7.2 to 29.9)

29.7 ± 10.4 (21.1 to 46.5)

5.4 ± 1.4 (3.3 to 8.2)

Single‐isocenter

7.5 ± 13.4 (3.2 to 13.5)

21.0 ± 8.9 (7.5 to 36.8)

36.1 ± 13.8 (18.2 to 61.7)

6.0 ± 1.8 (3.7 to 9.2)

P‐value

0.09

0.03

0.01

0.03

Statistically signiﬁcant P‐values are highlighted in bold.

insigniﬁcant, except for dose to 15 cc of heart (P = 0.002) and
dose to 10 cc of ribs (P = 0.02). Both the single‐isocenter and

3.C | Delivery efﬁciency and accuracy

two‐isocenter plans were within clinically acceptable limits per

For single‐isocenter plans, the mean values of total number of MUs

RTOG 0915.

and beam on time were 6014 (4013 to 10,727) and 4.3 min (2.9 to
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two‐isocenter plans, the actual patient setup and veriﬁcation for the
second isocenter plan would take extra‐time, prolonging the treatment
delivery. In addition, lower total MUs could potentially deliver lower
leakage dose. The complete details regarding number of MUs, beam‐
on time, VMAT QA gamma pass rates, and the measured point dose
percent difference are found in Table 4. Since the isocenter location
for single‐isocenter was under the MLC, the maximum point dose was
measured at the middle of the targets where the maximum ﬂuence
was delivered off axis to the two targets and compared to the computed VMAT QA plan on Octavius phantom.
The Octavius VMAT QA pass rates for the single‐isocenter plan
F I G . 3 . Scatter plot: For all eight lung SBRT patients, the ratios of V5,
V10 and V20 of normal lung doses calculated by single‐isocenter and
two‐isocenter plans as a function of isocenter to tumors distance. For
the identical planning objectives, the single‐isocenter plan gave slightly
higher values of V5, V10, and V20 by a factors of 1.2, 1.1, and 1.1, on
average, respectively, compared to two‐isocenter plan. This suggests
that comparable dosimetric parameters can be obtained for the normal
lung. However, single‐isocenter plan would have considerably faster
treatment delivery by an almost a factor of 2, eliminating the setup and
veriﬁcation time for the second isocenter plan.

was 98.1 ± 3.0%, on average, for 3%/3 mm clinical gamma pass rate
criteria and the point dose measurement was about within 1%, on
average, suggesting that an accurate delivery of the lung SBRT plan.
However, for patient #2, the gamma pass rates were around 92% for
3%/3 mm criteria. In this case, both tumors were relatively large, and
the tumors to isocenter distance was relatively large, around 9.5 cm.
In addition, the tumors were located in the bilateral lungs, therefore,
the MLCs have to travel a longer distance, providing suboptimal
VMAT QA pass rates; suggesting that exceeding 10 cm (isocenter to

7.7 min). For each clinical single‐isocenter plan, actual beam‐on time

tumors distance) may not provide clinically optimal plan with single‐

was recorded at the treatment machine (to verify the calculated beam

isocenter. While reanalyzing those data with a tighter distance‐to‐

on time) while delivering VMAT QA plan as mentioned earlier. For all

agreement (3%/2 mm) criteria, the average value of gamma pass rate

cases reported here, the maximum dose rate of 1400 MU/min for 6X‐

was 95.8 ± 3.8% (ranged, 90.6 to 100%) that was within the depart-

FFF beam was used. That (dose rate) was reviewed for each VMAT arc

mental SBRT VMAT QA pass rate criteria (>/=90.0% pass rates).

for all patients under the MLC properties tab. In addition, maximum

Since, the two‐isocenter plans were not used for actual patient's

dose rate of 1400 MU/min was visually observed (all the time) at the

treatment we did not run VMAT QA for those plans.

Octavius VMAT QA delivery at Truebeam for all clinical single‐isocenter/two‐lesion lung SBRT plans. This suggest that for these high dose
(high MUs) per fraction treatment the beam on time was dictated by

4 | DISCUSSION

total number of MUs per arc (as expected) rather than gantry rotation
speed. Compared to two‐isocenter plans, the total number of MUs

In this study, we have presented our initial clinical experiences of a

and beam on time were reduced by a factor of 1.5. Furthermore, with

fast, effective, and accurate treatment planning and delivery

T A B L E 3 Average values of absolute dose differences between single‐isocenter and two‐isocenter plans for the other major dose distribution
parameters of the OARs for all eight lung SBRT patients.
OARs
Spinal cord

Heart

Esophagus

Trachea

Ribs

Skin

Parameters

Mean ± SD (Gy)

Range (Gy)

Ratioa

P‐value

Dmax

0.5 ± 1.1

−0.9 to 2.9

1.05 ± 0.13

0.25

D0.35cc

0.5 ± 1.1

−0.7 to 2.7

1.03 ± 0.13

0.62

Dmax

0.9 ± 3.0

−5.4 to 5.0

1.07 ± 0.14

0.42

D15cc

2.0 ± 1.2

0.0 to 3.9

1.15 ± 0.09

0.002

Dmax

2.1 ± 3.9

−4.5 to 3.5

1.13 ± 0.23

0.18

D5cc

1.9 ± 3.3

−3.3 to 4.6

1.18 ± 0.31

0.15

Dmax

0.7 ± 1.8

−5.0 to 5.9

1.13 ± 0.27

0.55

D4cc

−0.8 ± 1.8

−4.5 to 1.0

0.96 ± 0.27

0.27

Dmax

0.0 ± 3.9

−5.1 to 7.4

0.99 ± 0.08

0.98

D1cc

−0.1 ± 2.2

−4.5 to 2.4

0.99 ± 0.07

0.91

Dmax

−0.6 ± 1.5

−3.9 to 0.6

0.97 ± 0.07

0.28

D10cc

1.2 ± 1.1

−0.4 to 2.8

1.11 ± 0.08

0.02

Absolute dose differences = single‐isocenter–two‐isocenter. The negative sign indicates that the results of the two‐isocenter plans were larger than
those of single‐isocenter plans. Statistically signiﬁcant P‐values are highlighted in bold.
a
Single‐isocenter/two‐isocenter.
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T A B L E 4 The detailed information on total number of MUs and beam‐on time for the both single‐isocenter and two‐isocenter plans for all
eight lung SBRT patients. The Octavius VMAT‐SBRT QA pass rates and point dose measurements for single‐isocenter plans were also shown.
Patient no.
1

Plan type
Two‐isocenter

2

3

4

5

6

7

8

Mean ± SD

Total no. of MUs

Beam‐on time (min)

Gamma pass rates 3%/3mm (%)

Point dose % diff. (%)

10,069

7.19

—

—

Single‐isocenter

5777

4.13

99.3

0.9

Two‐isocenter

13,198

9.43

—

—

Single‐isocenter

10,727

7.66

91.7

1.8

Two‐isocenter

9095

6.50

—

—

Single‐isocenter

6607

4.72

100.0

1.5

Two‐isocenter

7185

5.13

—

—

Single‐isocenter

6029

4.31

100.0

2.3

Two‐isocenter

6219

4.44

—

—

Single‐isocenter

4093

2.92

99.4

0.3

Two‐isocenter

9047

6.46

—

—

Single‐isocenter

5047

3.61

94.3

0.4

Two‐isocenter

5608

4.01

—

—

Single‐isocenter

4149

2.96

100.0

0.4

Two‐isocenter

10,500

7.50

—

—

Single‐isocenter

5680

4.06

100.0

0.7

Two‐isocenter

8865 ± 2330

6.3 ± 1.7

—

—

Single‐isocenter

6014 ± 1963

4.3 ± 1.4

98.1 ± 3.0

1.04 ± 0.7

technique using single‐isocenter VMAT plans for SBRT of two lung

compared to IMRT plans, Tomotherapy plan also gave a relatively

lesions following RTOG 0915 protocol guidelines.12 Our single‐iso-

higher normal lung V5. Another study by Li et al.30 reported that they

center VMAT plan for SBRT of two lung lesions uses 3–4 noncopla-

treated two patients with single‐isocenter lung SBRT plan for more

nar partial arcs with jaw tracking and patient speciﬁc collimator

than ﬁve lung metastases lesions. Their prescription doses were

angles to minimize leakage dose from leaves travelling in between

48 Gy/8 fractions for Patient A (5 tumors) and 42 Gy/7 fractions for

the tumors. Single‐isocenter VMAT‐SBRT plans were highly confor-

patient B (7 tumors). Plans were generated in Monaco TPS (CMS

mal and achieved adequate target coverage (see Table 1 for CI, HI,

Software Inc., St Louis, MO) using a few partial‐arcs and delivered

Paddick CN, GI, D2cm, and GD) compared to conventional two‐iso-

with Elekta Axesse linear accelerator with 6 MV beam (660 MU/min).

center plans. For all patients, the single‐isocenter plans met RTOG

The beam on time for each treatment was about 10 min. Both

guidelines including normal lung V20 and were similar compared to

patients were followed up, and the treatment was well‐tolerated by

two‐isocenter plans. However, when the isocenter to tumors distance

the patients with a minimal toxicity. In contrast, utilizing 6 MV‐FFF

increased, the low dose volume to the normal lung, such as V5 and

beam (in Eclipse) for Truebeam Linac our single‐isocenter VMAT plan-

V10, was slightly increased as shown in Fig. 3. In addition, the other

ning technique delivered fast (average beam on time 4.3 min) and

OARs such as spinal cord, heart, esophagus, trachea, ribs, and skin

effective treatment (curative high biological effective dose of >100–

dose tolerances were also within protocol. The single‐isocenter treat-

150 Gy for each lesion) for relatively large cohorts of patients.

ment was well‐tolerated with all patients. The beam on time was

One potential concern for single‐isocenter VMAT‐SBRT plan for

4.3 min and VMAT‐SBRT QA gamma passing rates were 98.1% (3%/

two lung lesions was low dose spill in the normal lung, such as V20,

3 mm clinical gamma passing criteria), on average, demonstrating an

V10, and V5. Per RTOG recommendation, all our single‐isocenter/

excellent potential for a fast, reliable, and accurate delivery of single‐

two‐lesions VMAT lung SBRT plans had V20 < 10–15%. Moreover,

isocenter VMAT lung SBRT treatment for two lung lesions.

normal lung V5 was maintained less than 40%, on average.31–33

The single‐isocenter plan for treating multiple lung tumors has
29,30

Although, in our experience when the isocenter to tumors distance

For instance, using both

increased, the normal lung V10 and V5 slightly increased, as

coplanar and noncoplanar nine ﬁelds IMRT (in Pinnacle TPS), Zhang

expected, when compared to two‐isocenter plan. Our treatment

et al.29 compared those IMRT plans with helical Tomotherapy for sin-

planning strategy favored minimizing normal lung dose during single‐

gle‐isocenter/multitarget lung SBRT treatment. The prescription was

isocenter VMAT planning (by optimizing patient speciﬁc collimator

60 Gy in three fractions. In their study, it was concluded that com-

angles in conjunction with jaws tracking such that the leakage dose

pared to IMRT, helical Tomotherapy gave better target coverage at

due to the leaves travelling in between two tumors could be mini-

the cost of overall 73.0 ± 20.6 min treatment time. However, IMRT

mized) that could potentially help reduce severe lung toxicity with

treatment time was not reported. It was also highlighted that

careful attention to V5 and V10 during plan optimization.

been reported by a few investigators.
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Another potential concern for single‐isocenter VMAT plan was the

reviewing these target volumes and the associated tumor motion

patient setup errors, for example tumor motion and rotational errors.

pattern and by assigning appropriate ITV to PTV margins (usually

This may result in geographic miss and compromise the local tumor

5 mm in the medio‐lateral and anterior–posterior directions and 8 to

control rates due to deformation. For single‐isocenter/two lesions

10 mm in superior–inferior direction) to accommodate potential

VMAT plan isocenter was generally chosen at the midpoint of the two

tumor deformation. Moreover, great care has been taken by our

lesions, therefore, the isocenter distance between two lesions was

treating physician and the physicist to address some of the above‐

evenly distributed. However, it would be difﬁcult to ﬁnd a perfect mid-

mentioned issues, for example, being available for the patient setup

point for noncoplanar lesions. The variability in respiratory patterns

(in the 3D, 4D CT simulation and each treatment), image guidance,

between the CT simulation and the time of treatment was studied by

and CBCT matching and physically authorizing each treatment frac-

many researchers.34–37 It has been reported in the literature that there

tion for all patients. However, it is worthwhile to mention here that

were only small changes (within ±3 mm) due to intrafractional and

the 8–10 mm superior–inferior expansion of the ITV to PTV is not a

interfractional motion while using conventional multi‐isocenter lung

requirement for an effective treatment of two lung lesions using a

SBRT treatment. Their mean patient setup time from tumor localiza-

single‐isocenter plan, but this was really only a conservative prefer-

tion to the end of treatment CBCT scan was about 40 min.36,37 It was

ence of our treating physicians from their many years of lung SBRT

recommended that a 5 mm PTV margin was sufﬁcient to address

experiences. Further studies are required to validate the standard

those motion errors. Furthermore, the spatial uncertainties for this

5 mm ITV to PTV expansions that would be adequate or not for this

kind of beam arrangement were discussed by Dr. Gary A Ezzell for sin-

kind of treatment setting while fulﬁlling the RTOG compliance.

gle‐isocenter/multitarget cranial radiosurgery.38 In his paper it has

In summary, each plan was rigorously evaluated using the dosi-

been demonstrated that for Truebeam CBCT the maximum spatial

metric parameters listed in the Tables 1, 2, and 3. All parameters

uncertainties were less than 1.5 mm at 10 cm distance from the

were deemed acceptable for both single‐isocenter and two‐isocenter

isocenter tested using 12 targets bearing balls (BBs) phantom. Before

plans per SBRT protocol ‐ suggesting that single‐isocenter plan could

delivering each SBRT treatment, a daily quality assurance check on

be dosimetrically equivalent to two‐isocenter plan and a faster and

kilovoltage to megavoltage imaging isocenter coincidence was per-

equally effective treatment delivery which can be offered to well sui-

formed, including IsoCalc test for precise and accurate target localiza-

ted patients. In the future, these patients will be followed up clini-

tion. Our IsoCalc localization accuracy for Truebeam was <0.5 mm at

cally and evaluated for local control rates and treatment related

isocenter. In addition, our off‐axis localization accuracy was similar to

toxicity such as the effect of normal lung dose as a function of

that of previously reported values by Dr. Ezzell while measured using

isocenter to tumors distance. Moreover, single‐isocenter VMAT plan

an IsoCalc QA phantom embedded with the multiple BBs. All the qual-

for SBRT of lung for more than two lesions will be investigated.

ity assurance procedures were in compliance for SBRT treatment
delivery. Our image guidance CBCT matching parameters (at Truebeam) were consistent with those previous ﬁnding.

5 | CONCLUSION

For our single‐isocenter/two‐lesion lung SBRT treatment, in addition to abdominal compression, the synchronous tumor motion was

This report presents our initial clinical experience with a single‐iso-

captured at the 4D CT simulation and appropriate PTV margins were

center for two‐lesion SBRT procedure for lung tumors and compared

applied for each tumor using MIP images. Using single‐isocenter plan

with conventional two‐isocenter plan. Treatment of peripherally

we have treated the PTV volume ranged from 5 to 90 cc (see

located two lung lesions with centrally assigned single‐isocenter was

Table 1). With this treatment technique, our clinical experience was

dosimetrically equivalent to two‐isocenter plan. For single‐isocenter

that treating small tumors off axis would need an additional margin

plans, it was observed that as the distance between the lesions

to minimize residual spatial uncertainties as mentioned above. On

increased the normal lung V5, V10 and MLD somewhat increased.

the other hand, treating larger tumors off axis may potentially spill

The single‐isocenter technique was fast, accurate, and very well‐tol-

low/intermediate dose to the normal lungs due to the MLC transmis-

erated by all the patients, improving patient comfort and potentially

sion. Our treating physicians are aware of these dosimetric charac-

reducing the amount of intrafraction motion errors for well‐suited

teristics and those residual spatial uncertainties were accounted

patients. Clinical follow‐up of these patients is warranted to deter-

during target delineation. However, our average beam on time of

mine the tumor local control rates and treatment related toxicity.

about 4.3 min per treatment could potentially decrease the possibility of changes on breathing signals from coughing or pain and mak-
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ing geographic miss unlikely‐potentially improving patient stability.
In addition, due to rotational errors, for small targets and those
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away from the single‐isocenter could potentially alter the dose distributions. For those highly conformal VMAT plans, the small deviation
in motion error could potentially irradiate normal tissues, and it may
increase the chance of radiation‐induced toxicity or miss the target.
Our attending physician has addressed that issue by individually
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